News & Updates
Filter by Specialty:
Tirzepatide beneficial for shedding pounds in obese adults
Once-weekly treatment with tirzepatide in adults with obesity appears to yield substantial and sustained reductions in body weight, according to the phase III SURMOUNT-1 trial.
Tirzepatide beneficial for shedding pounds in obese adults
21 Jul 2022
Chronic hepatitis C tied to cardiovascular events in T2DM
In patients with type 2 diabetes mellitus (T2DM), chronic hepatitis C and fatty liver appear to worsen the risk of cardiovascular events, a recent Taiwan study has found.
Chronic hepatitis C tied to cardiovascular events in T2DM
19 Jul 2022
Resmetirom demos potential in NASH
Safety analysis of the phase III MAESTRO-NAFLD-1 trial presented at ILC 2022 demonstrated the potential of resmetirom as a treatment for patients with non-alcoholic steatohepatitis (NASH) who have liver fibrosis.
Resmetirom demos potential in NASH
18 Jul 2022
Serum CTRP4 tied to coronary artery disease in T2DM
In patients with type 2 diabetes mellitus (T2DM), higher serum levels of circulating C1q tumour necrosis factor-related protein 4 (CTRP4) appear to aggravate the likelihood of coronary artery disease, a recent study has found.
Serum CTRP4 tied to coronary artery disease in T2DM
17 Jul 2022
Family history plus obesity/hyperglycaemia redoubles renal cell cancer risk
The interaction between genetic and environmental factors, specifically obesity and hyperglycaemia, contributes to an increased risk of renal cell cancer (RCC), suggests a study.